Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma

• Main Authors: Yusuke Funakoshi (Author), Nobuhiro Hata (Author), Daisuke Kuga (Author), Ryusuke Hatae (Author), Yuhei Sangatsuda (Author), Yutaka Fujioka (Author), Kosuke Takigawa (Author), Masahiro Mizoguchi (Author)
• Format: Book
• Published: MDPI AG, 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA. To evaluate the clinical impact of bevacizumab as a first-line drug for glioblastoma, two randomized clinical trials,...